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Abstract
The Kv11.1 (hERG) K
+ channel plays a fundamental role in cardiac repolarization. Missense mutations in KCNH2, the gene
encoding Kv11.1, cause long QT syndrome (LQTS) and frequently cause channel trafficking-deficiencies. This study
characterized the properties of a novel KCNH2 mutation discovered in a LQT2 patient resuscitated from a ventricular
fibrillation arrest. Proband genotyping was performed by SSCP and DNA sequencing. The electrophysiological and
biochemical properties of the mutant channel were investigated after expression in HEK293 cells. The proband manifested a
QTc of 554 ms prior to electrolyte normalization. Mutation analysis revealed an autosomal dominant frameshift mutation at
proline 1086 (P1086fs+32X; 3256InsG). Co-immunoprecipitation demonstrated that wild-type Kv11.1 and mutant channels
coassemble. Western blot showed that the mutation did not produce mature complex-glycosylated Kv11.1 channels and
coexpression resulted in reduced channel maturation. Electrophysiological recordings revealed mutant channel peak
currents to be similar to untransfected cells. Co-expression of channels in a 1:1 ratio demonstrated dominant negative
suppression of peak Kv11.1 currents. Immunocytochemistry confirmed that mutant channels were not present at the
plasma membrane. Mutant channel trafficking rescue was attempted by incubation at reduced temperature or with the
pharmacological agents E-4031. These treatments did not significantly increase peak mutant currents or induce the
formation of mature complex-glycosylated channels. The proteasomal inhibitor lactacystin increased the protein levels of
the mutant channels demonstrating proteasomal degradation, but failed to induce mutant Kv11.1 protein trafficking. Our
study demonstrates a novel dominant-negative Kv11.1 mutation, which results in degraded non-functional channels
leading to a LQT2 phenotype.
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Introduction
The KCNH2 gene encodes the Kv11.1 a-subunit (previously
referred to as hERG; human ether-a `-go-go related gene) of the
rapidly activating delayed rectifier K
+ (IKr) current; the predom-
inant component of cardiac repolarization [1]. To date, over 200
known KCNH2 mutations have been described causing a variant of
long QT syndrome, known as LQT2. The resulting loss of
function in IKr from these mutations can cause syncope or sudden
death due to ventricular tachyarrhythmias triggered by early
afterdepolarizations [2–4]. Standard treatment for patients with
LQT2 includes an implantable cardioverter-defibrillator and b-
blocker therapy, but there exists a need to develop more tailored
treatments as the specific molecular mechanisms underlying
LQT2 vary widely.
A predominant cause of Kv11.1 channel dysfunction in LQT2
involves trafficking deficiencies of mutant channels [5]. Single
point mutations (missense) in KCNH2 consistently yield channels
characterized by altered or impaired current amplitudes or kinetics
[6]. While the vast majority of missense mutations yield
nonfunctional channels, some truncated mutants are capable of
forming functional channels [7–10]. Truncated nonsense mutants
can also arise from insertion or deletion mutations producing
premature stop codons. In general, these nonsense LQT2 mutants
reside at the distal C-terminus, downstream of highly conserved
stretches of amino acids including the pore region and domains
required for tetramerization, maturation, stability and surface
expression of Kv11.1channels [11–13]. Interestingly, numerous
LQT2 trafficking-deficient mutants can be rescued following
specific non-physiologic manipulations of the cell culture condi-
tions [14]. For example, functional rescue has been achieved
following 24 h incubation at reduced temperature (,27uC) [15],
incubation with high-affinity pore-blockers (E-4031, cisapride)
[15–17], proteasomal inhibitors (lactacystin, MG132, ALLN)
[18–20], lysosome inhibitors (leupeptin; bafilomycin) [18,20,21],
or aminoglycoside antibiotics (G-418, gentamicin) [10].
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18273In the present study, we characterized a novel LQT2 mutation
Kv11.1-P1086fs+32X, causing ventricular fibrillation, which
results in dominant-negative suppression of wild-type (wt)
Kv11.1 current amplitude. Conventional strategies to rescue
channel trafficking were unsuccessful despite the fact that the
truncation mutation was located at the distal C-terminus.
Incubation of mutant channels with the proteasomal inhibitor
lactacystin significantly increased protein expression levels,
suggesting that the mechanism underlying dysfunction of this
mutant channel involves proteasomal degradation.
Methods
Ethics statement
The study protocol conformed to institutional standards and to
the Declaration of Helsinki. Written consents were obtained from
both patients for clinical testing.
Clinical evaluation
Patients underwent a physical examination and were assessed
for baseline electrolytes as well as evaluated by a 12-lead ECG and
echocardiogram assessed using standard criteria. Blood samples
were obtained and genomic DNA was extracted then amplified
using polymerase chain reaction. Patients were screened for LQTS
types 1–5 ion channel mutations using a commercial system
(FAMILION; PGxHealth, New Haven, CT). Ion channel muta-
tions were confirmed following reamplification, subcloning and
restriction digestion. An intravenous epinephrine stress test (0.05
to 0.2 mg/kg/min over 15 minutes) was also performed in the
proband’s asymptomatic brother as previously described [22].
DNA constructs
The human Kv11.1 pSP64 DNA was generously provided by
Dr. Michael Sanguinetti [23] (University of Utah) and the amino
terminal hemagglutinin (HA)-tagged wild-type (wt) Kv11.1
construct was kindly provided by Dr. Alvin Shrier (McGill
University, Montreal, QC) [11]. The Kv11.1 frameshift mutation
(P1086fs+32X; 3256InsG) was prepared using a Quikchange II
site-directed mutagenesis kit (Stratagene, La Jolla, CA). The
primers were as follows: Sense: 59-gct gtg acc acc ccg ggg gcc tgg
ccc cac ttc cac atc c- 39; Antisense: 59- gga tgt gga agt ggg gcc agg
ccc ccg ggg tgg tca cag c-39. The N-terminal hemaggluttinin (HA)-
tagged Kv11.1-wt served as a template. Channel constructs were
confirmed by sequencing and the protein was verified with
Western blot analysis.
Cell culture, transfection and drug treatments
HEK293 cells were grown at 37uC in a humidified 5% CO2
incubator. Cell culture medium was Dulbecco’s Minimum
Essential Medium (DMEM) (Invitrogen, Burlington, ON) con-
taining 4.5 g/L glucose and L-glutamine supplemented with 10%
fetal bovine serum and penicillin/streptomycin (100 units/mL;
100 mg/mL). HEK293 cells were transiently transfected using
Lipofectamine
TM 2000 (Invitrogen) according to the manufactur-
er’s instructions. Transient transfection of constructs consisted of
2.0 mg Kv11.1-wt or Kv11.1-mut, 1.0 mg Kv11.1-wt and 1.0 mg
Kv11.1-mut or 1.0 mg Kv11.1-wt for the equivalent of a 35 mm
dish. A Kv11.1-wt construct possessing a HA-tag (Kv11.1-HA-wt)
was used in some experiments. For electrophysiology experiments,
cells were also co-transfected with green fluorescence protein
(GFP) (0.25 mg) to visualize positively transfected cells, and 24 h
after transfection, cells were trypsinized and placed in 35 mm
dishes in low density and cultured overnight for single-cell
electrophysiological recordings. For biochemical experiments, cells
were grown in 100 mm dishes and the amount of DNA used was 6
times that mentioned above. Twenty-four hours after transfection,
some cells were incubated at 30uC incubator or with specific drugs
for 24 h before use in electrophysiological or molecular biology
experiments. These drugs included 5 mM E-4031 (Calbiochem,
San Diego, CA) and 20 mM lactacystin (Sigma-Aldrich Canada,
Oakville, ON) that were prepared as stock solutions dissolved in
water. Cells were washed and incubated in drug-free medium for
1 h before electrophysiological experiments.
Electrophysiology
Voltage-gated K
+ channel (Kv11.1) recordings of single cells
were performed using the whole-cell configuration of the patch
clamp technique. Recordings were acquired using a HEKA EPC-
10 amplifier operating at a sampling rate of 2.5 kHz and low-pass
filtered at 2.0 kHz and recorded with Pulse software (HEKA
Electronics Inc, Mahone Bay, NS). Pipettes were pulled from
1.5 mm borosilicate glass capillary tubes (World Precision
Instruments, Sarasota, FL) using a programmable micropipette
puller (Sutter Instrument, Novato, CA). Pipettes were heat
polished and resistances were obtained ranging from 2–4 MV
when filled with a solution containing (in mM): 140 KCl, 1 MgCl2,
5 EGTA, 10 HEPES, 5 MgATP (pH 7.2 with KOH). The bath
solution contained (in mM): 140 NaCl, 4 KCl, 1 CaCl2, 1 MgCl2,
10 glucose, and 5 HEPES (pH 7.4 adjusted with NaOH). Once
whole-cell configuration was established, cells were held at
280 mV and subjected to various experimental protocols. All
recordings were performed at room temperature (,22uC). No leak
subtraction was used during current recording and current
densities were normalized to cell capacitances.
Kv11.1 gating kinetic analysis was performed as previously
described by Zhou and colleagues [24]. Briefly, Kv11.1 activation
time constants were obtained by fitting the rising phase of
continuous currents following 3 s depolarizing pulses from 230 to
0 mV with a mono exponential function. At test potentials greater
than 0 mV, time constants were obtained by fitting families of
envelope tail currents produced at various voltages (20, 40 and
60 mV) because of the influence of channel inactivation.
Deactivation kinetics were measured from tail currents (2120 to
220 mV) following a prepulse depolarization to +60 mV.
Decaying tail currents were fit with a double exponential function.
Steady-state inactivation was assessed using a triple-pulse protocol
consisting of a 2-s depolarizing pulse to +60 mV followed by step
repolarizations from 2140 to +20 mV. Data were fit with a
Boltzmann function. The time constants for Kv11.1 fast
inactivation were obtained using the triple-pulse protocol function.
A prepulse depolarization of +60 mV was followed by a rapid
2100 mV repolarizing pulse and subsequent step depolarizations
220 to +60 mV were fit with a mono exponential function. Time
constants for recovery from inactivation were obtained using a
brief depolarizing pulse to +60 mV followed by repolarizing pulses
from 2100 to 220 mV. The resulting currents were fit with a
mono exponential function.
Western blot
HEK293 cells were grown to similar confluences and
transfected with the indicated cDNA constructs. Lysis buffer
contained 0.5% Nonidet P-40 buffer; 50 mM Tris HCl (pH=8.0);
75 mM NaCl and protease inhibitor cocktail (Roche Diagnostics
Canada, Laval, QC). Lysates were cleared of DNA and cellular
debris, protein concentrations were determined and equal
amounts of lysate (20 mg/lane) were subjected to SDS-polyacryl-
amide gel electrophoresis (7.5% gel) followed by transfer onto
PVDF membranes. After blocking, membranes were incubated
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(APC-016, 1:2000; Alomone, Jerusalem, Israel) or against the HA-
epitope (H-9658, 1:5000; Sigma) and secondary antibodies were
horseradish peroxidase-conjugated (Jackson Immunoresearch,
West Grove, PA). Signals were detected using ECL plus (GE
Healthcare, Baie d’Urfe, QC) and exposed to X-ray films, which
were developed using an automated photo-processor device.
Co-immunoprecipitation
HEK293 cells grown on 100 mm plates were transfected with
Kv11.1-wt and Kv11.1-mut constructs and harvested after 48 h
incubation. Cells were lysed with buffer containing 1% Triton X-
100, 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM CaCl2, and
a protease inhibitor cocktail (Roche). Lysates were precleared with
a 50% slurry of Protein A Sepharose CL-4B resin (GE Healthcare)
and supernants were subsequently retained for incubation with
Protein A beads and 2 mL of antibody. Reciprocal co-immuno-
precipitation was performed with anti-Kv11.1-wt antibody
(epitope corresponding to C-terminal 16 amino acids) or anti-
HA antibody for recognition of the mutant Kv11.1 channels. After
binding overnight at 4uC, complexes were washed 3–4 times with
wash buffer containing 0.1% Triton X-100, 10 mM Tris-HCl
pH 8.0, and 150 mM NaCl. Boiling the samples prior to SDS-
PAGE eluted proteins and membranes were immunoblotted for
the putative interacting protein partner.
Immunocytochemistry and confocal microscopy
HEK293 cells were transfected with Kv11.1-wt and Kv11.1-
mut constructs as well as GFP (0.25 mg) and were subsequently re-
plated onto glass coverslips 24 h after transfection. After an
additional 12–24 h, cells were fixed with 2% paraformaldehyde.
For total Kv11.1 protein expression, cells were permeabilized with
0.5% Triton X-100 and probed with an anti-HA antibody (Sigma,
H-2095), while total surface membrane Kv11.1 was probed in
non-permeabilized cells with an anti-Kv11.1 antibody (Alomone,
APC-109) that recognizes an extracellular 16-amino acid epitope
located between S1 and S2. The antibody was tested and
determined to have roughly equivalent binding affinity to both
Kv11.1-wt and Kv11.1-mut constructs. Cells were blocked with
5% goat serum, incubated with primary antibodies for 2 hours at
room temperature and then incubated with CY3-conjugated
secondary antibodies for 1 hour at room temperature. Cells were
also incubated with Alexa Fluor 633-phalloidin (1:40) for
20 minutes at room temperature and DAPI (1:2000) for 3 minutes
at room temperature. Imaging was performed on a 4-channel
Olympus FV1000 laser scanning confocal microscope with a 606
oil immersion objective, and with diode laser excitations at
405 nm for DAPI, 473 nm for GFP, 559 nm for Alexa 568 and
635 nm for Alexa 633. Untransfected cells, and cells transfected
with only GFP served as negative controls. All groups within each
experiment were imaged with the same signal amplitude, gain and
laser intensity. Images are of representative cells for each
transfection condition.
Data analysis and statistics
Electrophysiological measurements were analyzed using Micro-
cal Origin v6.0 (OriginLab Corporation, Northampton, MA).
Digital images of molecular biology experiments were quantified
Figure 1. 12-lead ECG of proband and sibling. QTc prolongation was observed before (A) and after (B) electrolyte restoration. C: The
asymptomatic sibling carried the same LQT2 mutation and ECG demonstrated mild QTc prolongation with biphasic T waves. D: Epinephrine stress
testing was consistent with definite LQTS. Blue arrows denote ST elevation.
doi:10.1371/journal.pone.0018273.g001
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blot band optical density was calculated by determining the sum of
the pixel intensity for each band subtracted by the average
background. Line scan analyses of single-slice confocal images
were obtained using Olympus Flouview Version 1.7 software
(Olympus Corporation, Markham, ON). For all figures, data
points represent mean 6 S.E.M. and ‘‘n’’ is the number of
experiments per group. Origin was used to analyze data and fit
exponential functions to raw current traces. An unpaired Student’s
t test was used to compare control values to experimental groups.
In experiments comparing more than 2 groups, one-way analysis
of variance (ANOVA) for repeated measures was calculated and
followed by Bonferroni’s post hoc test to assess differences between
groups. A p,0.05 was considered statistically significant.
Results
Patient Characteristics and Mutation Analysis
The proband was a 33-year old female with no prior cardiac
history, who suffered a ventricular fibrillation arrest following a
minor automobile accident. There was no family history of
sudden death or syncope. Her serum electrolytes on presenta-
tion were significant for severe hypokalemia and hypomagne-
semia (K
+=2.7mM; Mg
2+=0.63mM; and Ca
2+=2.1mM).
Her baseline 12-lead ECG showed marked QTc prolongation
(554 ms) with a broad-based T wave that was not related to
medications (Figure 1A). Echocardiogram showed no structural
heart disease with normal biventricular size and function.
Following correction of her electrolyte abnormalities, her QTc
remained prolonged (490 ms) and her T waves became biphasic
(Figure 1B). The proband was diagnosed with LQTS and
treated with an implantable cardioverter-defibrillator along
with oral Mg
2+ and K
+ supplementation and b-blocker therapy.
The proband’s 28-year-old brother was asymptomatic, but
manifested mild QTc prolongation (451 ms) with bifid T waves
and resting ST segment elevation (Figure 1C). Following
epinephrine stress testing, his uncorrected QT interval pro-
longed by .30 ms accompanied by the development of
biphasic T waves and prominent U waves, consistent with
LQTS (Figure 1D). Therefore, he was placed on prophylactic
b-blocker therapy.
Sequence analysis revealed that the proband and her brother
both possessed a point mutation in KCNH2. A guanosine insertion
in the codon sequence at nucleotide 3256 produced the frameshift
mutation localized at the Kv11.1 channel C-terminus
(P1086fs+32X; Figure 2). As a result, a premature stop codon
occurred downstream of 32 nonsense amino acids producing a
truncated 1118 amino acid Kv11.1 channel a-subunit. This point
mutation is located downstream of the cyclic nucleotide binding
domain (residues 750–870) [25] and the R-X-R ER-retention
Figure 2. Kv11.1 a-subunit schematic and sequence of channel mutation. A: Located at the C-terminus, the P1086fs+32X (3256InsG)
mutation is caused by a guanosine insertion in the codon at position 3256 (2356InsG), which elicits a frameshift at proline 1086 and produces 32 new
amino acids before a premature stop codon. The mutation is downstream of the cyclic nucleotide binding domain (cNBD) and produces a truncated
channel subunit. The N-terminus contains the Per Arnt Sim domain (PAS) and a HA-tag. B: Sequences for Kv11.1-wt and Kv11.1-mut (P1086fs+32X)
including the nonsense 32 amino acid sequence.
doi:10.1371/journal.pone.0018273.g002
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tetramerizing coiled-coil domain (residues 1018–1122) [13].
Properties of Kv11.1 P1086fs+32X channels
To assess the properties of the Kv11.1-mut channels, Western
blotting was performed and total Kv11.1 protein expression was
quantified (Figure 3A and B). HA-tagged constructs allowed for
the simultaneous detection of full-length Kv11.1-wt and Kv11.1-
mut channel protein. We observed a similar protein expression
level when both 2.0 mg and 1.0 mg of Kv11.1-wt construct was
transfected in 35 mm dishes. The total Kv11.1 protein expression
was normalized to 2.0 mg Kv11.1-wt control (n=4 experiments
per group). Total Kv11.1 protein expression for 1.0 mg Kv11.1-wt
alone and 1.0 mg Kv11.1-wt+1.0 mg Kv11.1-mut was not different
from control (0.8460.05 and 0.8060.14, respectively). However,
the total Kv11.1 protein expression level for 2.0 mg Kv11.1-mut
was significantly reduced compared to Kv11.1-wt control
(0.2560.09; p,0.01) and there was a complete absence of the
corresponding mature complex-glycosylated Kv11.1 band. The
KV11.1-wt 155 kDa complex glycosylated band was noticeably
absent in the co-transfection group despite roughly normal total
protein expression levels.
To examine the possibility of heterotetrameric channel
formation following coexpression, we performed reciprocal co-
immunoprecipitation on Kv11.1-wt and Kv11.1-HA-mut chan-
nels (Figure 3C and D). This was achieved by utilizing a non-HA-
tagged Kv11.1-wt construct and a Kv11.1 antibody corresponding
to a 16 amino acid epitope located at the distal C-terminus of the
wild-type channel. Alternatively, HA-tagged Kv11.1-mut was
immunoblotted using the standard anti-HA antibody. The
channels strongly interacted; however, we could not detect the
presence of a mature complex-glycosylated protein band at
155 kDa, indicating that heterotetrameric channels do not
undergo normal protein maturation.
Heterologous expression with Kv11.1-wt and Kv11.1-mut in a
1:1 ratio resulted in a suppression of Kv11.1 current amplitude at
all voltages positive to 220 mV, indicating a dominant-negative
suppression of wild-type current (Figure 4A). The current-voltage
relationship revealed that peak current amplitudes at +20 mV
were significantly reduced following coexpression of Kv11.1-wt
Figure 3. Biochemical analysis Kv11.1 protein expression and binding. A: Immunoblot of equal amounts of protein lysates (25 mg) from HEK
cells transfected with 1.0 or 2.0 mg of Kv11.1 cDNA. Kv11.1-wt channels expressed two protein bands corresponding to an immature core-
glycosylated 135 kDa ER-resident Kv11.1 protein [wt-(I)], and a mature complex-glycosylated 155 kDa Kv11.1 band [wt-(M)]. Mutant Kv11.1 channels
produced a single band at a slightly lower molecular weight (predicted to be 4 kDa smaller than Kv11.1-wt, thus approximately 131 kDa)
corresponding to an immature core-glycosylated Kv11.1-mut protein [mut-(I)]. B: Densitometric analysis of total Kv11.1 protein (n=4 experiments)
demonstrated that Kv11.1-mut transfections resulted in significantly less total Kv11.1 protein expression than control or co-transfection (ANOVA
*p,0.01). C,D: Reciprocal co-immunoprecipitation of Kv11.1-wt and Kv11.1-mut channels. Cells were transfected with a Kv11.1-wt construct lacking
the HA-tag and Kv11.1-HA-mut. Co-immunoprecipitation was performed with anti-Kv11.1-wt antibody (C) (epitope corresponding to C-terminal 16
amino acids) or anti-HA antibody (D) for recognition of Kv11.1-mut. The two channel constructs strongly interacted. (W is a sample in which primary
antibody was excluded during binding; IP: immunoprecipitation; IB: immunoblot).
doi:10.1371/journal.pone.0018273.g003
Characterization of Kv11.1-P1086fs+32X Channels
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e18273and Kv11.1-mut constructs (Figure 4B). Following normalization,
these three groups possessed identical current-voltage profiles and
normal C-type inactivation (Figure 4B, inset). Kv11.1-mut alone
did not produce measurable currents and were not different from
cells transfected with GFP alone.
Peak tail current amplitudes measured at 260 mV immediately
following a +60 mV pulse, were also reduced following coexpres-
sion of Kv11.1-wt and Kv11.1-mut constructs (Figure 4C).
Individual tail currents for each group were normalized and fit
to a Boltzmann function to determine the voltage-dependence of
current activation and produce a steady-state activation curve
(Figure 4C, inset). There was no difference in slope or V1/2
parameters between these groups (Table 1). Additionally, Kv11.1-
mut constructs alone did not produce any measurable tail currents,
suggesting that mutant constructs did not form functional
channels.
We performed an exhaustive assessment of Kv11.1 channel
kinetics but observed no differences in the rates of activation,
deactivation, recovery, fast inactivation and steady-state inactiva-
tion parameters following coexpression of Kv11.1-wt and Kv11.1-
mut channel constructs (Figure 5 and Table 1). This evidence
strongly suggested that P1086fs+32X affects the total number of
Figure 4. Kv11.1 P1086fs+32X mutation reduces peak current amplitude following coexpression with Kv11.1-wt. Electrophysiological
properties of Kv11.1-wt and Kv11.1-mut channels were assessed using whole-cell patch clamping. A: Families of current tracings from 280 to +60 mV
following 3 s step depolarizations. Kv11.1-wt currents were reduced following coexpression with Kv11.1-mut, indicating a dominant-negative
suppression currents. Kv11.1-mut constructs were indistinguishable from GFP-transfected controls. B: The current-voltage relationship demonstrated
that peak current amplitude is significantly reduced following coexpression (2.0 mg Kv11.1-wt, 57.764.6 pA/pF, n=16; 1.0 mg Kv11.1-wt,
51.466.3 pA/pF, n=14; 1.0 mg Kv11.1-wt+1.0 mg Kv11.1-mut, 25.362.0 pA/pF, n=10, p,0.001 from Kv11.1-wt). Peak Kv11.1-mut currents were
similar to GFP-transfected cells (2.0 mg Kv11.1-mut, 6.560.8 pA/pF, n=15 versus 0.25 mg GFP, 5.160.5 pA/pF, n=5). The current-voltage profile and
C-type inactivation properties were identical following normalization (inset). C: Peak tail currents were measured immediately following
repolarization. Kv11.1-wt+Kv11.1-mut tails were significantly reduced compared to control (2.0 mg Kv11.1-wt, 52.862.8 pA/pF, n=16; 1.0 mg Kv11.1-
wt, 43.563.9 pA/pF, n=14; 1.0 Kv11.1-wt+1.0 mg Kv11.1-mut, 25.962.6 pA/pF, n=10; p,0.01 from Kv11.1-wt). Tail currents were normalized and fit
to a Boltzmann function to assess the steady-state activation properties (inset). No changes in slope or V1/2 parameters were observed.
doi:10.1371/journal.pone.0018273.g004
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most likely does not alter the open probability of channel opening.
Total Kv11.1 protein cellular localization and expression was
assessed by immunocytochemistry and confocal microscopy
(Figure 6). Single plane XY confocal scans were taken through
cells, and line scans through the plasma membrane and
perinuclear regions were used to demonstrate differences in the
expression patterns of Kv11.1 channels at these distinct intracel-
lular locations. Kv11.1-wt protein was detected throughout the
cytoplasm and at the plasma membrane and was in contrast to
Kv11.1-mut cells, which had dense punctate intracellular protein
expression with periplasmic distribution. Co-expression of both
plasmids resulted in a hybrid staining phenotype with punctate
staining throughout the cytoplasm and less plasma membrane
expression.
Specific surface expression of Kv11.1 channels was determined
by probing non-permeabilized cells using an anti-Kv11.1 antibody
that recognizes an external epitope located between the S1 and S2
Table 1. Summary of steady-state channel kinetics.
Steady-state activation characteristics
Midpoint of current activation VK (mV): Slope factor: n-value
KV11.1-wt 23.1860.85 7.6060.36 10
KV11.1-wt+KV11.1-mut 24.3561.09 7.5960.21 14
Steady-state inactivation characteristics
Midpoint of current inactivation VK (mV): Slope factor: n-value
KV11.1-wt 245.1562.47 20.661.87 6
KV11.1-wt+KV11.1-mut 246.861.71 20.160.65 8
doi:10.1371/journal.pone.0018273.t001
Figure 5. Detailed analysis of Kv11.1 kinetics. Channel kinetics were compared between Kv11.1-wt and Kv11.1-wt+Kv11.1-mut groups as no
appreciable currents could be measured from Kv11.1-mut alone. There was no difference in channel activation (A), deactivation (B), contribution of
the fast component to current decay (C), steady-state inactivation (D), fast inactivation (E) or recovery from inactivation (F).
doi:10.1371/journal.pone.0018273.g005
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possessed robust expression of Kv11.1 protein at the plasma
membrane, as exemplified by the line scan histogram of the
merged image. Kv11.1 expression was not detectable in Kv11.1-
mut cells. Coexpression of Kv11.1-wt and Kv11.1-mut yielded
reduced plasma membrane Kv11.1 expression and areas of
punctate staining at the membrane. GFP co-transfection was used
as a negative vehicle control for cells not transfected with a
channel construct (Figure 7D).
Mechanism of P1086fs+32X dominant-negative
suppression of Kv11.1 channel function
Numerous trafficking-deficient LQT2 mutants can produce
functional channels following incubation at reduced temperature.
We tested whether P1086fs+32X+Kv11.1-wt trafficking could be
rescued following 24 h incubation at 30uC (Figure 8A and B),
which yields the highest expression levels of functionally active
mature Kv11.1 channels in vitro [27]. We compared immunoblots
of transiently transfected cells at 37uC and 30uC using anti-HA
and anti-Kv11.1 (C-terminal epitope) antibodies. Reduced tem-
perature had no effect on total Kv11.1 protein signal in any of the
groups, and more critically, it did not increase the expression nor
yield a mature 155 kDa Kv11.1 band following coexpression of
1.0 mg Kv11.1-wt (no HA-tag)+1.0 mg Kv11.1-HA-mut channels.
In support of these biochemical assays, whole-cell electrophysio-
logical measurements did not substantially increase peak Kv11.1
currents at +60 mV (Figure 8C). Similarly, peak tail currents
measured at 260 mV following the +60 mV step were not
significantly enhanced following reduced temperature incubation
(Figure 8D).
We hypothesized that the P1086fs+32X Kv11.1 mutation
results in proteasomal degradation, thereby preventing both
homotetrameric mutant channels, and heterotetrameric channels
from undergoing the normal maturation process including
complex glycosylation and cell-surface expression. Therefore, we
tested the specific proteasomal inhibitor lactacystin (20 mM, 24 h)
before harvesting cells for Western blot analysis (Figure 9A and B).
Lactacystin treatment significantly increased the ratio of total
Kv11.1-mut protein normalized to untreated Kv11.1-mut cells
versus 2.0 mg Kv11.1-wt control and 1.0 ug Kv11.1-wt+1.0 mg
Kv11.1-mut normalized to their untreated controls. Finally,
electrophysiological recordings showed no change in peak
Kv11.1-mut currents at +20 mV following treatment with
lactacystin (2.0 mg Kv11.1-mut, 6.560.8 pA/pF, n=15 versus
2.0 mg Kv11.1-mut+lactacystin, 6.860.7 pA/pF, n=3).
We further hypothesized that combination treatment of
Kv11.1-mut channels with proteasomal inhibition and reduced
temperature may enhance channel maturation and trafficking.
This combination did not significantly alter total Kv11.1 protein
expression, nor induce the appearance of a mature Kv11.1 protein
band by Western blot (not shown). We alternatively tested the
high-affinity Kv11.1 channel blocker E-4031, which has also been
Figure 6. Total Kv11.1 protein expression in fixed, permeabilized cells. The staining patterns for cells co-transfected with GFP (green) and
HA-tagged Kv11.1 plasmids (CY3, red) were assessed using immunocytochemistry and confocal microscopy. A: Kv11.1-wt; B: Kv11.1-mut; C: co-
expression of both plasmids. Untransfected cells served as negative controls (D). DAPI stained nuclei (blue) and phalloidin stained actin filaments
(CY5, purple) were used to identify the nucleus and plasma membrane, respectively. White arrows indicate the location of line scans through the
plasma membrane and perinuclear regions of merged images. Profile histograms indicate the fluorescence intensity for pixels along line scans for
each group. Scale bar represents 20 mm.
doi:10.1371/journal.pone.0018273.g006
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hour treatment with 5 mM E-4031 alone enhanced the expression
of the 155 kDa mature Kv11.1 band in the Kv11.1-wt and
Kv11.1-wt+Kv11.1-mut groups, but did not affect the expression
Kv11.1-mut control (Figure 9C). Additionally, combination
treatment with 5 mM E-4031 and 20 mM lactacystin had no
significant effect on Kv11.1-mut protein expression and did not
promote the appearance of a mature Kv11.1 protein band in the
Kv11.1-mut group (Figure 9D).
Discussion
Main Findings
This study investigated the biophysical properties and molecular
characteristics of a novel LQT2 mutation P1086fs+32X that
resulted in dysfunctional Kv11.1 channels and a clinical
phenotype in our patient. Although the mutation is located at
the distal C-terminus, it does not undergo normal channel
maturation or trafficking to the plasma membrane. In coexpres-
sion systems, and most likely in our LQT2 patients, the mutation
suppresses wild-type Kv11.1 currents in a dominant-negative
fashion. The mutant protein is degraded and cannot be rescued
with previously described in vitro methods, including incubation at
reduced temperature, medium supplemented with high-affinity
channel blocker, proteasome inhibitor, or combination of these
treatments.
ER-retention sequence and proteasomal degradation
A number of C-terminal truncation and frameshift LQT2
mutants have been characterized and shown to produce functional
Kv11.1 channels when expressed alone [10,17,28,29]. Further-
more, numerous trafficking-deficient LQT2 mutants with abnor-
malities of the C-terminus can be rescued by utilizing the
aforementioned conditions. Therefore, we did not anticipate that
the P1086fs+32X LQT2 mutant would have such a profound
inhibitory effect on wild-type Kv11.1 channels. This mutation
occurs in the Kv11.1 channel tetramerizing coiled-coil domain
and is in close proximity to the R-X-R ER-retention sequence
[13,26]. It is therefore conceivable that this mutant channel could
interrupt normal channel folding including tetramerization and
maturation. Reciprocal co-immunoprecipitation demonstrated
that wild-type and P1086fs+32X channels interact, suggesting
that heteromeric proteins form. But the mutant channels undergo
proteasomal degradation; a process partially inhibited by lacta-
cystin treatment. Therefore, it is likely that the location of the
truncation and the addition of subsequent nonsense amino acids
may serve to expose the R-X-R ER-retention sequence, thereby
marking the mutant protein for proteasomal degradation [19].
The proteasomal protein degradation pathway has emerged as an
important mechanism of control of protein levels and function and
this study highlights the importance of the proteasomal degrada-
tion of IKr as a key determinant of the function of these ion
channels [30,31].
Figure 7. Membrane Kv11.1 protein expression in fixed non-permeabilized cells. Mature Kv11.1 protein expression was investigated using
an external Kv11.1 epitope (CY3, red). A: Kv11.1-wt; B: Kv11.1-mut; C: co-expression of Kv11.1-wt and Kv11.1-mut. GFP-transfected cells served as
negative controls (D); DAPI stained nuclei (blue); phalloidin stained actin filaments (CY5, purple). White arrows indicate the location of line scans
through the plasma membrane and perinuclear regions of merged images. Profile histograms indicate the fluorescence intensity for pixels along line
scans for each group. Black arrows indicate the approximate location of plasma membrane in the histogram panels. Scale bar represents 10 mm.
doi:10.1371/journal.pone.0018273.g007
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channel maturation
Homomeric Kv11.1-mut channels did not produce an additional
Western blot band corresponding to mature channel protein
following E-4031 treatment, nor did they elicit functional current.
However, the dominant-negative inhibition of Kv11.1-wt+Kv11.1-
mut heteromeric channels was partially attenuated by E-4031.
Under control conditions, the production of heteromeric proteins
yieldthephenotypeofmutantsubunits,whicharerecognized bythe
intrinsic quality control components of the ER-Golgi network,
targeting them for degradation [32]. In the presence of E-4031,
Kv11.1-wt+Kv11.1-mut channel trafficking may have been en-
hanced due to a pharmacological chaperone mechanism that is
believed to drive enhanced channel maturation efficiency [16].
Pharmacological chaperones may serve to disrupt the interaction of
immature Kv11.1 proteins with ER chaperone and quality-control
proteins including Hsp40 (40-kDa heat shock protein), Hsc70 (70-
kDa heat shock cognate protein), Hsp90 (90-kDa heat shock
protein), FLBP38, calnexin, and numerous other chaperones,
thereby protecting mutant proteins from degradation and alterna-
tively by attenuating digestion by enzymes such as trypsin [33–35].
Although this high dose pharmacological approach is not useful
therapeutically, it does serve to illustrate a key feature related to the
mechanism of Kv11.1 P1086fs+32X channel dysfunction in our
patients that possess both normal and mutant alleles [36]. Therefore
the heteromeric model is a more accurate representation of the true
pathophysiology in the clinical setting.
Implications for treatment of LQT2 syndrome
An interesting clinical observation in our study was that the
proband presented with severe hypokalemia at the time of
ventricular fibrillation arrest. Extracellular K
+ levels can specifically
regulate the cell-surface expression of Kv11.1 channels, and
hypokalemia may enhance Kv11.1 channel internalization and
Figure 8. Reduced temperature does not rescue Kv11.1-mut trafficking. A/B: Cells were incubated at 30uC for 24 h and total Kv11.1 protein
was assessed by Western blot. Reduced temperature did not change the intensity of the protein band nor cause the appearance of a Kv11.1-mut
mature protein band. Co-transfection of non-HA-tagged Kv11.1-wt and HA-Kv11.1-mut (1.0 mgw t +1.0 mg HA-mut; in lanes 3 and 7) allowed for the
specific identification of Kv11.1-mut protein (A; anti-HA antibody) and Kv11.1-wt protein (B; anti-Kv11.1 C-terminal antibody). C: Peak current-voltage
relationship for Kv11.1-mut alone at 37uC and 30uC revealed no change in current density (Kv11.1-mut at 37uC, 6.560.8 pA/pF, n=15 versus Kv11.1-
mut at 30uC, 8.860.9 pA/pF, n=4). D: Peak tail current amplitude did not significantly change with reduced temperature (Kv11.1-mut at 37uC,
21.860.3 pA/pF, n=15 versus Kv11.1-mut at 30uC, 2.162.0 pA/pF).
doi:10.1371/journal.pone.0018273.g008
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predicted to further reduce the current density of IKr channels
already impaired at baseline by the P1086fs+32X mutation in our
patient, thereby markedly prolonging the QT interval and
increasing the risk of torsade arrest in our proband. This may also
explain why the proband’s sibling was asymptomatic, as he is
normokalemic. Another clinical finding of note was the unusual
ECG in proband’s brother with resting ST elevation along with
bifid T waves. Although this phenotype has been described in
Brugada syndrome due to Na
+ channel mutations and gain-of-
function Kv11.1 mutant channels [39], it has not been previously
reported with dominant-negative Kv11.1 mutations associated with
LQT2. Given that both patients were screened for only a subset of
genes associatedwith LQT1-5, itis possiblethat the brotherharbors
yet identified mutations or polymorphisms in other proteins.
Conclusion
We have provided the first clinical description and in vitro
assessment of the P1086fs+32X LQT2 mutation. This mutation
was recently reported in a large clinical database from a multi-
center case-control study screening patients for LQT [40].
However, no clinical data or electrophysiological properties of
this mutation were provided. The characterization of this unique
LQT2 mutant Kv11.1 channel may provide structural informa-
tion about the Kv11.1 C-terminus, and provide insight related to
the process of proteasomal degradation of LQT2 mutants, and the
importance of this mechanism in controlling protein function
[30,31]. Clinically, this study stresses the importance of K
+
supplementation, maintenance and monitoring in LQT2 patients,
especially those that may be more susceptible to life-threatening
Kv11.1 channel dysfunction associated with severe loss-of-function
mutations.
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